Video

Dr. Antonarakis on the Benefits of Genetic Testing for Select Patients With Prostate Cancer

Emmanuel Antonarakis, MD, discusses the benefits of somatic and germline testing for patients with prostate cancer.

Emmanuel Antonarakis, MD, associate director for Translational Research, Clark Endowed Professor of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota Medical School Masonic Cancer Center, discusses the benefits of somatic and germline testing for patients with prostate cancer. 

Oncological and neurological guidelines recommend germline testing for patients with high-risk localized prostate cancer or positive pelvic lymph node disease, Antonarakis states. Conversely, patients with low-risk localized prostate cancer are not typically directed to undergo germline testing, with the exception of individuals with a family history of prostate cancer or a genetic background that may increase the risk of displaying a germline mutation.

Unlike germline testing, somatic testing is not generally recommended for this patient population, as there is currently no somatic-based treatment approach for patients in this setting, Antonarakis continues.

Finally, patients with metastatic prostate cancer are recommended to undergo germline and somatic genetic testing. The genetic information obtained could help clinicians choose an appropriate targeted gene therapy and provide counsel to patients with a hereditary risk of prostate and other cancers, Antonarakis concludes.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity